Table 1 Characteristics of included studies.

From: Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials

Study Year Indication Length of treatment Total CBD dose/daya Type of CBD Food directions Number of participants Age inclusion criteria Mean age Male (%) Clobazam co-prescription (%) Valproate co-prescription (%)
Consroe et al. [26] 1991 Huntington’s Disease 6 weeksb 10 mg/kg Not specified Empty stomach with a glass of water 18 47.8 61.1 0 0
GWP Fatty Liver Disease NCT01284634 [3] 2014 Fatty Liver Disease 8 weeks 200/400/800 mg Plant derived (GWP42003) Fasted, 30 min before meal 25 18+ 46.4 48
Jadoon et al. [2] 2016 Type II Diabetes 13 weeks 200 mg Plant derived (GWP42003) Fasted, 30 min before meal 27 18+ 57.7 63
Naftali et al. [25]c 2017 Crohn’s Disease 8 weeks 20 mg sublingual Plant derived 19 18–75 39 57.9
Devinsky et al. (GWPCARE1) [18] 2017 Dravet Syndrome 11 days titration and 12 weeks maintenance treatment up to 10 days taper period or OLE 20 mg/kg GWP42003-P, plant derived 120 2–18 9.8 52 65 59
Boggs et al. [19] 2018 Schizophrenia 6 weeks 600 mg Provided by STI Pharmaceuticals 41 18–65 47.4 69.4 ?d
McGuire et al. [4] 2018 Schizophrenia 6 weeks 1000 mg Plant derived (GWP42003) 88 18–65 40.8 58
GWP Clobazam Interaction Study NCT02565108 [20] 2018 Clobazam 10 days titration and 21 days maintenance treatment 10 day taper period or OLE 20 mg/kg Plant derived (GWP42003-P) 20 18–65 36.8 50 100
Devinsky et al. (GWPCARE1 – Dose Ranging) [21] 2018 Dravet Syndrome 3, 7 or 11 days titration 21 days maintenance treatment 10 days taper period or OLE 5/10/20 mg/kg Plant derived (GWP42003-P) 34 4–10 7.6 47 68 65
Devinsky et al. (GWPCARE3) [17] 2018 Lennox-Gastaut Syndrome 7 or 11 days titration 12 weeks maintenance treatment 10 days taper period or OLE 10/20 mg/kg Plant derived (GWP42003-P) 225 2–55 15.6 57.3 49 38
Thiele et al. (GWPCARE4) [22] 2018 Lennox-Gastaut Syndrome 11 days titration 12 weeks maintenance treatment 10 days taper period or OLE 20 mg/kg Plant derived (GWP42003-P) 171 2–55 15.4 51.5 49 40
Taylor et al. [23] 2018 Healthy Adults 1 week 1.5 g or 3 g per day (half dose on day 7) Plant derived (GWP42003) 24 18–45 26 33.3
Hill et al. NCT03102918 [24] 2019 Cannabis Use Disorder 6 weeks 800 mg Plant derived (GWP42003) 10 18–65 30.8 40 0 0
  1. OLE open-label extension.
  2. aOral dosing unless stated otherwise.
  3. bCrossover study with a 1 week washout and second 6 weeks treatment period, only pre-crossover data were extracted.
  4. cNaftali 2017 met all inclusion criteria but did not contribute data to meta-analysis.
  5. d25% of participants were prescribed a mood stabilizer which may include valproate.